Skip to main content
. Author manuscript; available in PMC: 2012 May 15.
Published in final edited form as: Clin Cancer Res. 2011 Apr 7;17(10):3219–3232. doi: 10.1158/1078-0432.CCR-11-0234

Figure 6. HDACIs potentiate KW2449 activity against IM-resistant ALL in vivo.

Figure 6

Figure 6

Figure 6

Figure 6

A) BV173/E255K cells stably transfected with Luc/pcDNA3 (BV173/E255K/Luc cl4) were injected into BALB/SCID mice via tail vein (2.5 × 106 cells). The mice were then injected with firefly luciferin and imaged by Xenogen once or twice weekly. Empty boxes represent deceased mice. B) Mice were treated with KW2449 (32 mg/kg po once daily; green line), vorinostat (70 mg/kg ip daily (orange line) or the combination of vorinostat+KW2449 (purple line). Mice were also injected with sterile water as a control control (blue line). Drugs were administered 5 days per week. Survival was evaluated from the first day of treatment until death using Kaplan-Meier curves, (* P<0.05). C) Mice were treated with KW2449 (32 mg/kg po daily, SNDX275 (15 mg/kg po daily) or the combination of SNDX+KW2449 or sterile water as a control. Drugs were administered 5 days a week, (* P<0.05). D). Cells from a representative bone marrow sample obtained from one mouse from each group after 3 weeks of treatment were stained with fluorescently-labeled CD19 and CD45 antibodies, after which they were analyzed by flow cytometry.